On March 20th, Alacrita Partner Edward Garmey, M.D., will moderate a distinguished panel titled “Clinical trials in early stage oncology development” at the 11th annual BIO-Europe Spring conference in Barcelona, Spain.

Edward is an experienced oncology drug development consultant based in Cambridge, MA. Dr. Garmey was formerly Chief Medical Officer and Senior Vice President at Cerulean Pharma, Inc., a clinical-stage oncology company based in Waltham, MA. focused on the design and development of nanopharmaceutical-drug-conjugates differentially directed to cancer cells. Prior to being appointed to Cerulean in 2011, Dr. Garmey served between 2008 and 2011 as Vice President for Clinical Development at ArQule, Inc., a publicly-traded cancer-focused biotechnology company located in Woburn, MA., where he developed and oversaw multiple international clinical trials of its lead product, ARQ 197 (tivantinib).

The panel being moderated by Dr. Garmey will include Carlos Buesa, CEO, Oryzon; Carlos López, Business Development Manager, Vall d'Hebron Institute of Oncology; Sonal Patel, VP, Oncology Scientific Innovation, Johnson & Johnson Innovation; Gemma Sala, Head, Clinical Trials Office for Phase I Trials, Vall d'Hebron Institute of Oncology/Barcelona Clinical Trials Platform; and Robert Wasserman, Chief Medical Officer, Northern Biologics. Discussion topics will include the difficulty of recruiting sufficient patient populations for oncology clinical trials. Participants in the accompanying workshop will learn how partnerships between biotech companies and large hospital research networks in early stage oncology trials can help facilitate development and give companies access to the technical and clinical research expertise provided through these networks